Photodepletion differentially affects CD4+ Tregs versus CD4 + effector T cells from patients with chronic graft-versus-host disease

Blood

Volumn 116, Issue 23, 2010, Pages 4859-4869

  Bastien, Jean Philippe ^a,b   Krosl, Gorazd ^a   Therien, Cynthia ^a   Rashkovan, Marissa ^a   Scotto, Christian ^a   Cohen, Sandra ^a,b   Allan, David S ^c   Hogge, Donna ^d   Egeler, R Maarten ^e   Perreault, Claude ^a,b   Roy, Denis Claude ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Leukemia/BMT Program of British Columbia   (Canada)

^e Kiadis Pharma   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIBROMORHODAMINE 123; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN P; INTERLEUKIN 10; RHODAMINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CONTACT; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY T LYMPHOCYTE;

EID: 78649710409     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-273193     Document Type: Article

References (50)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674): 1550-1561.
2. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414.
3. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19.
4. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009;114(18):3956-3959.
5. Sabry W, Le Blanc R, Labbe AC, et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant. 2009;15(8):919-929.
6. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762. (Pubitemid 44061381)
7. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid- resistant chronic GVHD. Blood. 2006;107(8): 3074-3080.
8. Flowers ME, Apperley JF, van Besien K, et al. A multicenter, prospective, phase 2, randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-2674.
9. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4):1515-1521.
10. Boumedine RS, Roy DC. Elimination of alloreactive T cells using photodynamic therapy. Cytotherapy. 2005;7(2):134-143. (Pubitemid 40872748)
11. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood. 2002;100(2):375-382.
12. Mielke S, Nunes R, Rezvani K, et al. A clinicalscale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2008; 111(8):4392-4402.
13. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graftversus- leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99(9):3083-3088.
14. Roy DC, Lachance S, Kiss T et al. Haploidentical Stem cell transplantation: high doses of alloreactive- T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without causing severe GVHD [abstract]. Blood. 2009;114:512.
15. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903-2911.
16. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
17. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108(4):1291-1297.
18. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versushost disease. Blood. 2007;110(5):1689-1697. (Pubitemid 47443988)
19. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111(2):945-953.
20. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
21. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T-lymphocyte clones. J Immunol. 1986;136(10):3543- 3548.
22. Zhang Y, Hexner E, Frank D, Emerson SG. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007;179(5):3305-3314.
23. Radojcic V, Pletneva MA, Yen HR, et al. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010;184(2):764-774.
24. Allan SE, Broady R, Gregori S et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev. 2008;223:391-421.
25. Fehervari Z, Sakaguchi S. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol. 2004;16(12): 1769-1780.
26. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995; 270(5238):985-988.
27. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-547.
28. + T cells. Eur J Immunol. 2007;37(1):129-138.
29. Biagi E, Di Biaso I, Leoni V et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T cells in patients with graftversus- host disease. Transplantation. 2007;84(1): 31-39.
30. Di Biaso I, Di Maio L, Bugarin C, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation. 2009;87(9):1422-1425.
31. Jonson CO, Pihl M, Nyholm C, Cilio CM, Ludvigsson J, Faresjö M. Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children. Clin Exp Immunol. 2008;153(2):174-181. (Pubitemid 351989154)
32. Maeda A, Schwarz A, Bullinger A, Morita A, Peritt D, Scharz T. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: generation of IL-10 and induction of regulatory T cells. J Immunol. 2008;181(9): 5956-5962.
33. George JF, Gooden CW, Guo L, Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. J Heart Lung Transplant. 2008;27(6):616-622.
34. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001;166(6): 3789-3796.
35. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T-cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26(5):579-591.
36. Manzotti CN, Tipping H, Perry LC, et al. Inhibition of human T-cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol. 2002;32(10):2888-2896.
37. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006; 177(7):4376-4383.
38. Andersson J, Tran DQ, Pesu M et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med. 2008;205(9):1975-1981.
39. Kullberg MC, Hay V, Cheever AW, et al. TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol. 2005; 35(10):2886-2895.
40. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T-cell function. Eur J Immunol. 2004;34(11):2996-3005.
41. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T-cell function. Science. 2008;322(5899):271-275.
42. Bodor J, Fehervari Z, Diamond B, Sakaguchi S. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol. 2007;37(4):884-895.
43. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002; 196(2):247-253. (Pubitemid 34787514)
44. Roncarolo MG, Gregori S, Battaglia M et al. Interleukin- 10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50.
45. Dulude G, Roy DC, Perreault C. The effect of graft-versus-host disease on T-cell production and homeostasis. J Exp Med. 1999;189(8):1329-1342.
46. Poulin JF, Sylvestre M, Champagne P, et al. Evidence for adequate thymic function, but impaired naïve T-cell survival, following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood. 2003; 102(13):4600-4607.
47. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005; 11(11):1238-1243.
48. Bosco N, Agenes F, Rolink AG, Ceredig R. Peripheral T-cell lymphopenia and concomitant enrichment in naturally arising regulatory T cells: the case of the pre-Talpha gene-deleted mouse. J Immunol. 2006;177(8):5014-5023.
49. Blais ME, Brochu S, Giroux M, et al. Why T cells of thymic versus extrathymic origin are functionally different. J Immunol. 2008;180(4):2299-2312.
50. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J Immunol. 2006;177(1):192-200.